

The Introduction of the High-end Bio-pharmaceutical Industry in Binhai New District, Shaoxing City

Shaoxing Binhai New District is the first batch of high-energy strategic platforms in Zhejiang province and one of the first new districts in Zhejiang Province. It also serves as a vital carrier for the full implementation of the national strategy for the integrated development of the Yangtze River Delta and the integrated development of Hangzhou-Shaoxing-Ningbo demonstration zone.

The new district spans a planning area of 430 square kilometers and is home to platforms such as a national high-tech zone, a national economic and technological development zone, and a national comprehensive bonded zone, in addition to two major provincial-level new industrial platforms in integrated circuits and bio-pharmaceuticals with the space more than 10,000 mu(≈ 6.67 km²) and the output value of one hundred billion RMB" . In 2023, the new district achieved a regional GDP of 924 billion RMB, marking an 8.2% increase year-on-year, ranking first among Zhejiang province's seven new districts and twelfth among top 100

national new districts with development potential.

During the golden age of development in the Greater Bay District in China, Shaoxing Binhai New District demonstrated strong economic potential and development vitality. In 2023, the new district's high-end bio-pharmaceutical industry platform entered into a period of rapid development, known as version 2.0. The platform gathered more than 200 companies, including 7 listed companies, achieving a total industrial output value of 35.67 billion RMB, a 9.4% increase year-on-year, with its comprehensive evaluation ranking continuing to rank fourth in Zhejiang province.

It is well known that the Yangtze River Delta region is a high ground for industrial development in China. Despite fierce regional competition, Binhai New District possesses strong comparative advantages in **geography, industry, innovation, and service**.

First, it has a geographical advantage. Situated on the south bank of Hangzhou Bay, Shaoxing Binhai New District connects Hangzhou, Ningbo, and Shanghai, serving as a crucial hub for sea-land transportation. It is connected to Shanghai Port and Ningbo Port, with Hangzhou Xiaoshan International Airport being reached

within a 30-minute drive and Ningbo Lishe International Airport one hour. It is traversed by Hangzhou-Ningbo Expressway, Hangzhou-Shaoxing-Taizhou Expressway, and Changzhou-Taizhou Expressway, with Hangzhou-Shaoxing-Ningbo Smart Expressway already being operational. The subway connecting Hangzhou and Shaoxing marks the entrance of "twin city era".

Second, it has an industrial advantage. By integrating existing foundations and proactively planning for the vast market of holistic health, it aims to build a comprehensive bi-pharmaceutical industry chain from biologicals to innovative medicines, medical devices, and health services, encompassing the entire life-cycle of health. By gathering leading enterprises such as Excellent Technology(TECT) and Tasly Holding Group Co., Ltd. in immune cells and stem cells, it creates a demonstration base on cell ecology. Led by locally nurtured leading enterprises such as Zhejiang Medicine Co., Ltd., Antengene Corporation Ltd., and Asclepis Pharmaceuticals Co., Ltd., in conjunction with innovative pharmaceutical companies like NovoCodex Biopharmaceuticals Co., Ltd., it forms a regional competitive advantage in innovative medicines. Relying on Zhende Medical Co., Ltd., it drives enterprises like CAS Ion Medical Technology Co., Ltd. (CASHIM) and forms a whole industry chain

from diagnosis to treatment and rehabilitation. With Beijing Jinkangpu Food Science & Technology Co., Ltd. as the leading enterprise, it has established a whole industry chain layout from raw material supply and precision formulation to Food for Special Medical Purpose,FSMP and public health.

Third, it has an innovation advantage. It clusters 42 provincial-level and above R&D institutions and possesses two provincial-level industrial innovation service complexes in modern medicine and medical devices, public service platforms such as the Drug Safety Evaluation Research Centre, Zhejiang Institute for Food and Drug Control, and the Headquarters Base of East China region, Shenzhen Academy of Metrology and Quality Inspection (Group) Limited Liability Company, and has reached cooperation intentions with six top provincial hospitals for clinical trial centers-Zhejiang Provincial People's Hospital, the First Affiliated Hospital, Zhejiang University School of Medicine and the Second Affiliated Hospital Zhejiang University School of Medicine, etc. It has received support for six National Science and Technology Major Projects, successfully launched four First in Class(FIC) on the market, and other 27 New Drugs have entered into different clinical stages. It has also deepened the construction of the pilot zone of talent

management and reform in Shaoxing Binhai New District, building a high-energy "industry-talent integration" platform with high standards.

Fourth, it has an service advantage. Shaoxing Binhai New District has always been supported by a six-chain model, aggregating all kinds of service. **In terms of policy support,** the "Bio-pharmaceutical Specialized Support Policy Version 3.0" has been introduced, providing multi-dimensional key supports for companies at different stages of development. **In terms of financial support,** the district fully brings into the leverage effect of 10 billion RMB FOF of the bio-pharmaceutical industry, forming more than ten direct investment projects and a group of sub-funds, mobilizing over 70 billion RMB of social capital, and driving industrial clustering through capital innovation. **In terms of carrier services,** it provides landing carriers for projects with industry parks planned with high threshold and constructed with high standard, such as CAS Life Health Science and Technology Innovation Park and Sinomedbay Zhejiang Precision Medicine Industry Park, etc. Moreover, it introduces a batch of platforms - CRO, CDMO, and CSO excel in service, such as Guoxin Pharmaceutical Technology (Beijing) Co., Ltd., strengthening, extending, and supplementing the

bio-pharmaceutical industry chain. **In terms of the business environment**, it has successively introduced "full life cycle" management methods for industrial land and industrial project, establishing a closed-loop service system. In every stage of a project, from signing to production, there is a designated lead unit responsible for addressing the issues, especially in project approvals, where a green channel has been established, ensuring priority approval, acceptance of incomplete applications, and parallel processing, providing "one-stop" tracking and commission services, significantly speeding up the approval process.